Silencing of HEK293 cells
For silencing, HEK293 cells were cultured in the growth medium containing charcoal stripped FBS (Gibco, Life Technologies GmbH, Germany). The cells were subsequently transfected with 10 nM validated NR3C2 siRNA (ID no. s8839, Ambion, Life Technologies GmbH, Germany), with 10 nM VDR siRNA (ID no. s14777, Ambion, Life Technologies GmbH, Germany), with 10 nM CYP27B1 siRNA (ID no. s3890, Ambion, Life Technologies GmbH, Germany) or with 10 nM negative control siRNA (ID no. 4390843, Ambion, Life Technologies GmbH, Germany) using siPORT amine transfection agent (Ambion, Life Technologies GmbH, Germany) according to the manufacturer's instructions. The cells were used 48 hours after transfection. The efficiency of silencing was verified by quantitative RT-PCR.
Animal experiments
All animal experiments were conducted according to the German law for the care and use of laboratory animals and were approved by local authorities. Experiments were performed in C57Bl6 mice under control diet and access to drinking water ad libitum. In a first study group, male and female mice were subcutaneously injected with vehicle (soybean oil), DOCA (50mg/kg BW), spironolactone (75mg/kg BW) or DOCA and spironolactone together [37] . Eight hours after injection, mice were sacrificed and kidney tissues were rapidly removed and immediately snap frozen. In another study group, male mice were treated with either spironolactone (80mg/L) [30] or with vehicle drinking water ad libitum and sacrificed after 5 days of treatment. Blood was collected by retroorbital puncture and the plasma concentration of 1,25(OH) 2 D 3 was determined by an EIA kit (Immunodiagnostic Systems, UK) according to manufacturer's instructions. Kidney tissues were rapidly removed after sacrificing the mice and immediately snap frozen.
Quantitative RT-PCR
Total RNA was isolated from mouse kidney tissues by using Trifast Reagent (Peqlab Biotechnologie GmbH, Germany) according to the manufacturer's instructions. HEK293 cells were washed with PBS and total RNA was isolated using Trifast Reagent (Peqlab, Biotechnologie GmbH, Germany) according to the manufacturer's instructions. Reverse transcription of 2 µg RNA was performed using oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers (Invitrogen, Life Technologies GmbH, Germany) and SuperScriptIII Reverse Transcriptase (Invitrogen, Life Technologies GmbH, Germany). cDNA samples were treated with RNaseH (Invitrogen, Life Technologies GmbH, Germany). Quantitative real-time PCR was performed with the iCycler iQ TM Real-Time PCR Detection System (Bio-Rad Laboratories GmbH, Germany) and iQ TM Sybr Green Supermix (Bio-Rad Laboratories, GmbH, Germany) according to the manufacturer's instructions.
Fisher Scientific, Rockford, IL, USA). After centrifugation at 10000 rpm for 5 min, protein concentration was determined by Bradford assay (Biorad Laboratories, Hercules, CA, USA). Proteins were boiled in Roti Load 1 protein loading buffer (Carl Roth, Karlsruhe, Germany) at 100°C for 10 min, separated on SDSpolyacrylamide gels and transferred to PVDF membranes [13] . The membranes were incubated overnight at 4°C with rabbit anti-CYP27B1 antibody (dilution 1:500, Santa Cruz, Dallas, Texas, USA), rat anti-α-klotho antibody (1:1000, kindly provided by Kyowa Hakko Kirin Co. Ltd, Japan) or rabbit anti-GAPDH antibody (1:1000; Cell Signaling, Danvers, MA, USA) and then with secondary anti-rabbit HRP-conjugated antibody (1:1000; Cell Signaling, Danvers, MA) or secondary anti-rat HRP-conjugated antibody (1:1000; Cell Signaling, Danvers, MA) for 1 hour at RT. For loading controls, the membranes were stripped in stripping buffer (Thermo Fisher Scientific, Rockford, IL, USA) at RT for 10 min. Antibody binding was detected with the ECL Western Blotting Substrate (Pierce, Rockford, IL, USA). Positive and negative controls were used to determine the molecular size of klotho protein in HEK293 cells. Bands were quantified using Quantity One Software (Bio-Rad, München, Germany) and results are shown as the ratio of total protein to GAPDH normalized to the control treated group.
Statistics
Data are provided as means ± SEM, n represents the number of independent experiments. All data were tested by ANOVA followed by post hoc analysis, or unpaired Student t-test where appropriate. P < 0.05 was considered statistically significant.
Results
The present study explored the interactions of the mineralocorticoid aldosterone and the moderately selective mineralocorticoid receptor antagonist spironolactone on KLOTHO gene expression. Human embryonic kidney cells (HEK293) were treated for 24 hours with aldosterone (100 nM) without and with simultaneous spironolactone treatment (10 µM). To avoid potential effects of endogenous ligands in the medium, the experiments were performed using charcoal-stripped FBS media. As illustrated in Fig. 1A , aldosterone treatment was followed by a significant decrease of KLOTHO mRNA levels. Spironolactone did not only reverse the effect of exogenous aldosterone but significantly increased KLOTHO mRNA levels beyond the values observed in control treated HEK293 cells. Cotreatment with both, aldosterone and spironolactone and treatment with spironolactone alone was followed by a statistically significant increase of KLOTHO mRNA levels (Fig. 1A) . This effect was paralleled by similar changes in CYP27B1 mRNA levels. Aldosterone tended to decrease CYP27B1 transcript levels in HEK293 cells, an effect, however, not reaching statistical significance (Fig 1B) . Similar to the observed effects of spironolactone on KLOTHO expression, spironolactone treatment significantly increased CYP27B1 gene expression ( Fig 1B) .
Similar observations were made in vivo. Treatment of mice with subcutaneous DOCA injection significantly decreased renal Klotho mRNA levels ( Fig. 2A) . Injection of spironolactone without or with additional DOCA injection significantly increased Klotho mRNA levels ( Fig. 2A) . Similar to the in vitro experiments, DOCA treatment tended to downregulate the renal Cyp27b1 transcript levels, an effect, however, not reaching statistical significance. Spironolactone treatment alone resulted in a statistically significant increase of Cyp27b1 mRNA levels (Fig. 2B) .
Another series of experiments explored, whether spironolactone similarly regulates klotho and CYP27B1 protein levels in HEK293 cells. As shown in Fig. 3A ,B, spironolactone treatment for 48 hours was followed by a statistically significant increase in klotho protein expression in HEK293 cells. This effect was paralleled by similar changes in CYP27B1 protein levels. Spironolactone treatment significantly increased CYP27B1 protein expression in HEK293 cells (Fig. 3C,D) .
Further experiments elucidated the effect of spironolactone on KLOTHO gene expression. In order to test, whether the increases of KLOTHO and CYP27B1 mRNA levels were mediated by inhibition of the mineralocorticoid receptor (encoded by the NR3C2 gene), the NR3C2 gene was silenced in HEK293 cells. As illustrated in Fig. 4 , silencing of NR3C2 did not significantly alter KLOTHO mRNA expression and thus did not mimic the effect of spironolactone. The subsequent treatment with spironolactone was followed by a statistically significant increase of KLOTHO gene expression to similarly high levels in HEK293 cells silenced with negative control siRNA and in HEK293 cells silenced with NR3C2 siRNA. Similar observations were made on CYP27B1 mRNA levels (Fig. 4) . Silencing of NR3C2 did not significantly modify CYP27B1 gene expression. Treatment with spironolactone was followed by a statistically significant increase of CYP27B1 mRNA levels to similarly high levels in HEK293 cells silenced with negative control siRNA and in HEK293 cells silenced with NR3C2 siRNA (Fig. 4) . Thus, the mineralocorticoid receptor NR3C2 may not be involved in the upregulating effect of spironolactone on KLOTHO and CYP27B1 gene expression in the absence of aldosterone.
As increased KLOTHO transcript levels were paralleled by increased CYP27B1 mRNA levels, additional experiments explored, whether the effect of spironolactone on KLOTHO mRNA Silencing of VDR did not significantly modify KLOTHO transcript levels. However, treatment with spironolactone was followed by a statistically significant increase of KLOTHO mRNA levels in HEK293 cells silenced with negative control siRNA, but not in HEK293 cells silenced with VDR siRNA (Fig. 5F) .
Additional experiments were performed to elucidate the effect of spironolactone on Klotho gene expression in vivo (Fig. 6 ). Mice were fed with control drinking water or with drinking water containing spironolactone (80mg/l) for 5 days. As shown in Fig. 6A , spironolactone treatment was followed by a statistically significant increase of Klotho mRNA levels. This effect was again paralleled by a significant increase of Cyp27b1 gene expression following spironolactone treatment (Fig. 6B) . However, no significant differences in klotho or CYP27B1 protein expression could be observed in the kidney tissues between spironolactone treated mice and control treated mice (data not shown). Moreover, the spironolactone treatment did not significantly modify plasma 1,25(OH) 2 D 3 levels (145.3 ± 6.2 and 150.4 ± 6.2 pmol/l; n=6; in control treated and spironolactone treated mice, respectively), renal Cyp24a1 mRNA expression (1.10 ± 0.18 and 1.41 ± 0.29 a.u.; n=8-9; in control treated and spironolactone treated mice, respectively) and renal Vdr mRNA expression (1.02 ± 0.07 and 1.09 ± 0.03 a.u.; n=8-9, in control treated and spironolactone treated mice, respectively).
Discussion
Mineralocorticoid receptor activation is associated with a variety of pathological disorders and mineralocorticoid receptor blockade has been shown to exert beneficial effects in several preclinical models and human studies [38] . The present study confirms the previous observation [13] that klotho expression is downregulated by aldosterone. The present observations demonstrate that the moderately selective mineralocorticoid receptor antagonist spironolactone [39, 40] does not only reverse the inhibitory effect of aldosterone on renal Klotho gene expression, but upregulates Klotho mRNA levels even in the absence of exogenous aldosterone. Despite low expression of KLOTHO in HEK293 cells due to promoter methylation, similar effects of spironolactone could be observed in those cells as in vivo [41, 42] . Spironolactone upregulated KLOTHO mRNA and protein levels even in charcoal-stripped FBS media, an observation pointing to an effect independent of mineralocorticoid receptor blockade. Along those lines, silencing of the mineralocorticoid receptor did not significantly modify KLOTHO mRNA levels and did not mimic the upregulation of KLOTHO mRNA levels following spironolactone treatment. Taken together, the observations suggest that spironolactone stimulates KLOTHO gene expression at least in part by a mechanism other than mineralocorticoid receptor blockade. As silencing did not completely abrogate NR3C2 expression, however, the present observation do not safely rule out involvement of the mineralocorticoid receptor. The effect of spironolactone on KLOTHO gene expression is paralleled by a similar regulation of CYP27B1 mRNA and protein levels. More importantly, the effect of spironolactone on KLOTHO gene expression is significantly blunted or virtually abrogated following silencing of either the 25-hydroxyvitamin D 3 1-alpha-hydroxylase or the vitamin D 3 receptor. Thus, spironolactone stimulates the 25-hydroxyvitamin D 3 1-alpha-hydroxylase leading to stimulation of 1,25(OH) 2 D 3 formation and subsequent activation of the vitamin D 3 receptor. Nevertheless, no significant differences in klotho or CYP27B1 protein levels could be observed between spironolactone treated mice and control treated mice. Possibly, the effect of spironolactone may have been too small to be apparent following analysis of the heterogenous tissues of whole kidneys. Furthermore, no significant increase in plasma 1,25(OH) 2 D 3 levels was observed following a 5 days treatment of mice with spironolactone, an observation possibly reflecing an auto-or paracrine effect [43] .
1,25(OH) 2 D 3 is a well-known stimulator of klotho expression [20, 44] [4] . Previous observations pointed to mineralocorticoid receptor-independent effects of spironolactone [47] [48] [49] [50] [51] . Although aldosterone activates NFkB, spironolactone additionally inhibits NFkB in a MR-independent manner [51, 52] . NFkB represses 25-hydroxyvitamin D 3 1-alpha-hydroxylase expression and treatment of HEK293 cells with an NFkB inhibitor increases Cyp27b1 expression [53] . In addition to blocking the effects of aldosterone, spironolactone could therefore increase Cyp27b1 expression and subsequent klotho expression by inhibiting NFkB activity independent of the mineralocorticoid receptor.
In patients with chronic kidney disease (CKD), klotho and 1,25(OH) 2 D 3 levels are strongly reduced, while phosphate levels are increased [10, 54, 55] . The increased phosphate levels in these patients are correlated with vascular calcification, a main factor in the mortality of those patients [56] . Despite the stimulatory effect of 1,25(OH) 2 D 3 on phosphate reabsorption, reduced levels of 1,25(OH) 2 D 3 are similarly associated with increased mortality in CKD patients [54] . Although previous studies in preclinical models suggested an adverse effect of calcitriol on vascular calcification, supplementation of 1,25(OH) 2 D 3 at physiological doses increased klotho levels and provided beneficial effects [57] [58] [59] . Moreover, 1,25(OH) 2 D 3 stimulates nitric oxide production [60] and modifies glucose metabolism. Accordingly, 1,25(OH) 2 D 3 may exert beneficial cardiovascular effects [61, 62] . The klotho protein similarly reduces vascular dysfunction, renal fibrosis and aging [17, 20, [63] [64] [65] . Klotho inhibits epithelial-to-mesenchymal transition, which was implicated in anti-cancerogenous effects of klotho [8, 16] . Spironolactone is protective in various models of renal and cardiovascular disease, an effect at least partly independent from lowering of blood pressure [66] [67] [68] [69] . The effects of spironolactone on in vivo Klotho mRNA expression were significant, but minor and presumably cannot fully account for the beneficial effects of spironolactone in various disease models [70] . Yet, the upregulation of Klotho expression is in accordance with the various vasculo-and reno-protective effects of spironolactone [70] . Mineralocorticoid receptor blockade may provide beneficial effects independently of klotho and 1,25(OH) 2 D 3 [30, 31, 38] . It is possible, however, that the upregulation of Cyp27b1 and Klotho could contribute to the protective effects of spironolactone. As especially in CKD patients, both 1,25(OH) 2 D 3 and klotho are reduced, the present observations suggest a possible benefit of spironolactone in CKD patients. Even though the potassium retaining effects of spironolactone are a concern especially in CKD patients, several studies do suggest that mineralocorticoid receptor blockers may be well tolerated by CKD patients [71] [72] [73] .
Conclusion
Cyp27b1 expression is upregulated by spironolactone by a mineralocorticoid receptorindependent mechanism, followed by a subsequent upregulation of klotho expression in
